On Thursday, Shares of Alaska Air Group, Inc. (NYSE:ALK), gained 1.74% to $ 61.82.
Alaska Airlines began selling tickets on newly-declared routes between Los Angeles and Costa Rica’s two major international airports. The eight weekly flights from Los Angeles to San Jose (SJO) and Liberia/Guanacaste (LIR), Costa Rica, are planned to start Oct. 31 and Nov. 1, respectively, subject to approval by the Costa Rican civil aviation authorities.
To inaugurate the new service, Alaska is offering introductory one-way fares of $249 from Los Angeles to San Jose and Liberia/Guanacaste. One-way fares for customers connecting from Seattle and Anchorage to San Jose and Liberia/Guanacaste are as low as $299 and $369 one-way, respectively. To take advantage of these low fares, customers must purchase their tickets by June 17 and travel by Jan. 28, 2016.
Alaska Air Group, Inc., through its auxiliaries, provides passengers and cargo air transportation services primarily in the United States. The company operates through Alaska Mainline and Alaska Regional segments.
Shares of Jumei International Holding Ltd(ADR) (NYSE:JMEI), declined - 0.79% to $ 22.67, during its last trading session.
Jumei International Holding, declared that it will meet with institutional investors at the following forthcoming investor conferences in June 2015:
- On June 16-17, Ms. Mona Gao and Mr. Sterling Song will meet with investors at the UBS Asian Consumer Conference at UBS offices in Hong Kong.
- On June 23-25, Ms. Mona Gao and Mr. Sterling Song will meet with investors at the Macquarie Securities China Internet, Media & Technology Conference at the Grand Hyatt Hotel in Beijing.
Jumei International Holding Limited operates as an online retailer of beauty products in the People’s Republic of China. The company offers beauty products, such as cosmetics, skin care, cosmetic applicators, fragrance, and body care products; and beauty products for men, and baby and children.
At the end of Thursday’s trade, Shares of KKR & Co. L.P. (NYSE:KKR), gained 1.13% to $ 23.31.
Bayer AG has reached a definitive agreement to sell its Diabetes Care business to Panasonic Healthcare Holdings Co., Ltd., a company which is backed by funds sponsored by leading global investment firm KKR and the Panasonic Corporation. The total consideration for the transaction is EUR 1,022 million (JPY 138 billion). The sale will comprise the leading Contour portfolio of blood glucose monitoring meters and strips, in addition to other products such as Breeze 2, Elite and Microlet lancing devices. Closing of the transaction is subject to customary conditions, counting relevant antitrust clearance, and is predictable to occur in the first quarter of 2016.
“We are confident that the sale of our Diabetes Care business to our long-standing partner Panasonic Healthcare, with the strong backing of KKR, will support the long-term sustainability of this portfolio,” said Werner Baumann, member of the Board of Administration of Bayer AG and CEO of Bayer HealthCare.
KKR & Co. L.P. is a private equity and real estate investment firm specializing in direct and fund of fund investments. It specializes in acquisitions, leveraged buyouts, administration buyouts, credit special situations, growth equity, mature, mezzanine, distressed, and middle market investments.
Finally, Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), ended its last trade with -1.93% loss, and close at $ 6.59.
Progenics Pharmaceuticals, declared that the European Commission has approved RELISTOR(R) (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. The decision effective May 27, 2015 is applicable to all 28 European Union member states plus Iceland and Norway and comprises an additional one year of marketing protection. The European Commission decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) which cited that RELISTOR offers a major contribution to patient care in comparison to existing therapies.
RELISTOR was first approved in Europe in 2008 for the treatment of OIC in advanced illness patients, and is presently approved in more than 50 countries counting the United States.
Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates comprise prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has accomplished Phase II testing in chemotherapy-practiced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has accomplished Phase II testing, in addition to acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
